Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06533059 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

A Phase 1 study of Breast Cancer and Cancer, sponsored by Alterome Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
110
Enrollment target
20
Study locations

NCT06533059 is a Phase 1 study of Breast Cancer and Cancer that is actively recruiting participants, run by Alterome Therapeutics. The registered enrollment target is 110 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06533059, a Phase 1 study of Breast Cancer and Cancer, is actively recruiting participants, sponsored by Alterome Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
110 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Conditions Studied

Breast Cancer Cancer Advanced Solid Tumor Endometrial Cancer Metastatic Cancer

Interventions

  • DRUG ALTA2618

Study Locations (20)

Texas

  • Research Site - Dallas
  • Research Site - Houston
  • Research Site #2 - San Antonio
  • Research Site - San Antonio

California

  • Research Site - La Jolla
  • Research Site - Los Angeles

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

New York

  • Research Site - Mineola
  • Research Site - New York

New South Wales

  • Research Site - Blacktown
  • Research Site - Randwick

Colorado

  • Research Site - Denver

Florida

  • Research Site - Sarasota

Georgia

  • Research Site - Atlanta

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2024-08-22
Est. Completion 2027-12-29
Phase Phase 1

Sponsor

Alterome Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06533059

The ClinicalTrials.gov registry entry for NCT06533059 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Alterome Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ALTA2618 is the first listed.

NCT06533059 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06533059 about?

NCT06533059 is a clinical study titled "A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors". The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

What is the current status of trial NCT06533059?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2024-08-22. Estimated completion is 2027-12-29.

What conditions does trial NCT06533059 study?

This clinical trial studies the following conditions: Breast Cancer, Cancer, Advanced Solid Tumor, Endometrial Cancer, Metastatic Cancer.

What interventions are being tested in trial NCT06533059?

The interventions under investigation include: ALTA2618 (DRUG).

Who is sponsoring clinical trial NCT06533059?

This trial is sponsored by Alterome Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06533059 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.